Navigation Links
Early Research Suggests Umbilical Cord Blood Cell Therapy May Reduce Progression of Alzheimer's Disease
Date:3/27/2008

Study Highlights Growing Therapeutic Value of Cord Blood Stem Cells

OLDSMAR, Fla., March 27 /PRNewswire-FirstCall/ -- Stems cells derived from umbilical cord blood are showing early potential in fighting Alzheimer's disease, according to results from a new preclinical study published in the March issue of Stem Cells and Development. The study, conducted by researchers from the University of South Florida and Saneron CCEL Therapeutics, Inc., found that targeted immune suppression using stem cells derived from human umbilical cord blood reduced Alzheimer's disease progression in a mouse model. Alzheimer's disease is a progressive and incurable brain disease that affects more than five million people in the United States alone. The ongoing research project has been funded in part by Cryo-Cell International, Inc., an industry leader in stem cell innovation and one of the nation's largest and most established family cord blood banks. Additional study sponsors are the National Institutes of Health's STTR grant program, Florida High Tech Corridor Matching grant program, and the Johnnie B. Byrd, Sr. Alzheimer's Center and Research Institute."

An abundance of research conducted in the last two decades alone has demonstrated the life-saving potential of stem cells derived from umbilical cord blood. In fact, stem cells found in cord blood have been proven to treat more than 70 life-threatening illnesses, including leukemia, neuroblastoma, ischemic brain injury and Type 1 diabetes. Since the first successful cord blood stem cell transplant in 1988, cord blood stem cells have been used in more than 7,000 transplants. Each year, an estimated 12,000 Americans could benefit from a stem cell transplant.

"The scientific community has only skimmed the surface in uncovering the many potential therapeutic uses for cord blood stem cells, and this new research in Alzheimer's disease may pave the way for discoveries around the use of these cells for a host of ne
'/>"/>

SOURCE Cryo-Cell International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Cystic Fibrosis Foundation Announces Positive Early Results for Phase 2 Clinical Trial of VX-770 - an Oral Compound to Treat CF
2. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
3. Clinical Trial Best Practices: Savvy Marketers Plan Ahead with Early Communication Strategies
4. New Report Offers Hope for Closing Health Gap for African Americans, With Nearly 700 Medicines in Pipeline
5. PLC Systems Achieves Successful Early Conclusion of RenalGuard(TM) Pilot Safety Trial
6. Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection
7. New Data from the Framingham Heart Study Supports PAT Technology to Diagnose Early Cardiovascular Disease
8. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
9. Experts Call for Widespread Use of Memory Screenings and Emphasize Value of Early Detection of Dementia
10. Preclinical Studies Show Potential Progress Toward Identifying Specific Tumor Types With Higher Likelihood of Demonstrating Response to Anti-Cancer Compounds Early in Clinical Development
11. Potential Early Warning System for Lung Cancer Identified
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2008)... to Have Higher Sensitivity and Specificity, than...was the preferred test in all phas... 13 /- AT First Diagnostic LLC an,eme...ic test kits, today,announced that a recent evalua...f Research of the FirstVue(TM) HBSAG Test, was rel...
(Date:10/13/2008)...- Facet Solutions, Inc. today,announc...nts from its US,IDE Pilot Study. The results show ... scores, and an 80% reduction in Visual Analog Sco...resident & CEO for Facet Solutions,added, "We are... far not,only demonstrate significant pain relief ...
(Date:10/12/2008)...N, Oct. 12 /- Boston,Scient...ults from an analysis,of nearly 7,500 patients fro...esigned to confirm the performance of the TAXUS(R)...stem in real-world practice. The,two-year pooled A...nical,restenosis in patients with diabetes as effe...
(Date:10/10/2008)...is Treatment with Kogenate FS Reduces the,Risk of ...No Pre-Existing,Joint Damage, BERKELEY, Calif., O...ced today that the U.S. Food and Drug Administrati...enate(R) FS Antihemophilic Factor,(Recombinant) to... risk of,joint damage in patients aged 0-16 years ...
Breaking Medicine Technology:Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 2Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 3Walter Reed Evaluation Concludes FirstVue(TM) HBSAG Test is Preferred over Other Rapid Tests 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 2TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 3TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 4TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program 5FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5Shingles Pain Treatment Will Benefit More Patients 2872 1Shingles Pain Treatment Will Benefit More Patients 2872 2Shingles Pain Treatment Will Benefit More Patients 2872 3Shingles Pain Treatment Will Benefit More Patients 2872 4Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 1Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 2Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 3Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout RDEA594 Into Phase 1 Clinical Trial 2867 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 1Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 2Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 3Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 4Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 5Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 6Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 7Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 8Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 9Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 10Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 11Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 12Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 13Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 14Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 15Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 16Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 17Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 18Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 19Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 20Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results 7264 21New Health Knowledge Base and Semantic Search Engine Announced 25637 1New Health Knowledge Base and Semantic Search Engine Announced 25637 2
...d Insurance Coverage Varies,Greatly for Different ... 2007-- Most U.S. adults support,approving the use...act people,s quality of life, including birth cont...reat erectile,dysfunction and improve memory and t...ieve these types of treatments should be covered,b...
...y 1, 2007 - Progenics,Pharmaceuticals, Inc. (NASDA... first clinical trial of its investigational drug,...mmunodeficiency,virus (HIV), the causative agent o... of PRO 140 achieved an average maximum,decrease o...,log10), with individual reductions ranging up to ...
Other Medicine Technology:Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 2Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 3Eighty-one Percent of U.S. Adults say that Birth Control Pills and,Procedures Should Be Covered by Health Insurance 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 2Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 3Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 4Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 5Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 6Progenics Announces Positive Results in Clinical Trial of Novel HIV,Therapy 7
(Date:10/13/2008)...ges Latinos to Get Tested, LOS ANGELES, Oct. 13 /...half of all newly diagnosed HIV/AIDS cases,reporte...ionally., -- A week of activities aimed at raisin...ting to coincide with National Latino AIDS Awarene...r Community, Our Responsibility: Latinos in Action...
(Date:10/13/2008)...n ever before, study finds , , MONDAY,...ver are being treated for high blood pressure, say...nd Blood Institute. , The major factor in the d...igh blood pressure appears to be the obesity epide...dditional efforts are needed to prevent hypertensi...
(Date:10/13/2008)...g advances study Study needed because of low... 13 /PRNewswire/ -- Advanced Circulatory Systems, ...ced today that it has received,an additional $1.5 ...,Health (NIH) to continue a study testing two devi...rdiac arrest outside a hospital. Parts of Oakland,...
(Date:10/13/2008)...valve.com ) announced today that the expanded clin...aneous aortic valve replacement (PAVR) in high-ris...l patients at an accelerating pace. More than 1,80...ly 100 centers in 20 countries. , ...er 13, 2008 -- During the Monday Transcatheter Ao...
Breaking Medicine News(10 mins):Health News:Nearly Half of Newly Diagnosed HIV/AIDS Cases in Los Angeles County Are Among Latinos 2Health News:Blood Pressure on the Rise in America 2Health News:Blood Pressure on the Rise in America 3Health News:3 Michigan Counties Participating in NIH Study of Cardiac Arrest Resuscitation Techniques 2Health News: CoreValve Announces That More Than 1,800 High-Risk Patients Have Been Treated with its ReValving System for Percutaneous Aortic Valve Replacement (PAVR) : Highly encouraging registry data also presented at TCT 2008 2
...ofi-Aventis, one of the world's leading pharmaceut... Taxotere (docetaxel) improves survival in patient... clinical trial named TAX 327 compared Taxotere pl...one) plus prednisone. The study included a little ...
...nagers who use mobile phones for many hours a day ...ay develop psychological disorders, says a study t...s. // Francisca Lopez Torrecillas, a lecturer at t...chological assessment and treatment of the Univers...
...ian belief and knowledge are great healers and 140...rently in Delhi to study this value system. // "Th...tal role in dealing with mental health issues and ...re about it," said Patrick Bantman, a psychiatrist...
...en aiming to shed after-pregnancy pounds should ad...cording to a new study by Harvard researchers. // ...isk for weight gain in women,” said lead author Em...n that early postpartum period — such as diet, tel...
Other Medicine News:Health News:Mobile Phone Addiction may Cause Psychological Problems 2Health News:Simple Solutions to Postpartum Weight Retention 2
Spinal Concepts has developed a versatile set of instruments intended to make posterior lumbar interbody fusion procedures precise, simple and quick every time. The Harmony PLIF Instrument Set is the
Kerrison (Spurling) Laminectomy Rongeur. 15 cm - 6, thick footplate, large handle, 90 up-cutting, 2 mm wide.
Kerrison (Micro) Laminectomie Rongeur, with ejector. 18 cm - 7 1/8, with thick footplate, small handle, 90 up-cutting, jaws 2 mm wide.
OSV II Smart ValveTM, Hakim, H-V Lumbar Valve system is the intelligent choice for meeting the complex demands of hydrocephalus shunting. Automatic pressure response causes the valve to adjust automa
Medicine Products: